Navigating the landscape of targeted therapies for renal cell carcinoma in the era of precision medicine (Review)
- 1Department of Urology, Yantai Affiliated Hospital of Shandong Medical and Pharmaceutical University, The Second Clinical Medical School of Shandong Medical and Pharmaceutical University, Yantai, Shandong 264100, P.R. China
- 2Research and Translational Center for Immunological Disorders, Yantai Affiliated Hospital of Shandong Medical and Pharmaceutical University, Yantai, Shandong 264100, P.R. China
Abstract
Renal cell carcinoma (RCC) is a biologically heterogeneous malignancy characterized by dysregulation of angiogenic signaling, immune evasion and epigenetic remodeling. Advances in molecular profiling have redefined RCC as a pathway-driven disease, enabling the development of targeted therapies and immune checkpoint inhibitors (ICIs) that have notably improved clinical outcomes. The present review evaluated current evidence on the molecular basis and therapeutic landscape of RCC, with emphasis on von Hippel-Lindau-hypoxia-inducible factor signaling, chromatin remodeling alterations and immune regulatory pathways. The present review summarizes pivotal phase III clinical trials evaluating VEGF-targeted tyrosine kinase inhibitors, mechanistic target of rapamycin inhibitors, immune checkpoint inhibitors and combination regimens, including nivolumab plus ipilimumab, pembrolizumab + axitinib and lenvatinib + pembrolizumab. Emerging biomarkers, including International Metastatic Renal Cell Carcinoma Database Consortium risk stratification, programmed death-ligand 1 expression and chromatin remodeling gene alterations (polybromo 1/BRG1-associated factor 180, BRCA1-associated protein 1 and SET domain containing 2), are discussed in the context of their clinical utility and limitations. Despite marked progress, durable predictive biomarkers and optimal treatment sequencing strategies remain unresolved. Resistance to therapy emerges through adaptive angiogenic signaling, immune escape and metabolic reprogramming, underscoring the need for integrated multi-omics approaches and rational combination strategies. By integrating molecular biology with clinical trial evidence, the present review provides a structured framework for understanding therapeutic decision-making in RCC and highlights future directions toward biomarker-guided precision oncology.
Related
- The Evolving Landscape of Hypertrophic Cardiomyopathy: Clinical Assessment, Precision Therapies, and Emerging Strategies
- Long-term prophylaxis for hereditary angioedema: Navigating the switch between therapies☆
- Navigating T-Cell-Directed Therapies in Transformed Follicular Lymphoma
- Comprehensive regulatory and developmental landscape of cell–scaffold combination therapies for osteoarthritis
- Hippo pathway in cancer ferroptosis: from mechanism insights to targeted therapies
BibTeX
@article{cui2026navigating,
title = {{Navigating the landscape of targeted therapies for renal cell carcinoma in the era of precision medicine (Review)}},
author = {Hongguo Cui and Jingheng Song and Peisen Yang and Zhengchao Zhang and Yuanyuan Liu and Gang Zhang and Aimin Tian and Jizhong Che and Yangyang Liu and Hui Sun and Yankai Xu},
journal = {Molecular Medicine Reports},
year = {2026},
month = oct,
doi = {10.3892/mmr.2026.14041},
url = {https://doi.org/10.3892/mmr.2026.14041},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Navigating the landscape of targeted therapies for renal cell carcinoma in the era of precision medicine (Review)
AU - Hongguo Cui
AU - Jingheng Song
AU - Peisen Yang
AU - Zhengchao Zhang
AU - Yuanyuan Liu
AU - Gang Zhang
AU - Aimin Tian
AU - Jizhong Che
AU - Yangyang Liu
AU - Hui Sun
AU - Yankai Xu
PY - 2026
DA - 2026/10/13
JO - Molecular Medicine Reports
DO - 10.3892/mmr.2026.14041
UR - https://doi.org/10.3892/mmr.2026.14041
AB - Renal cell carcinoma (RCC) is a biologically heterogeneous malignancy characterized by dysregulation of angiogenic signaling, immune evasion and epigenetic remodeling. Advances in molecular profiling have redefined RCC as a pathway-driven disease, enabling the development of targeted therapies and immune checkpoint inhibitors (ICIs) that have notably improved clinical outcomes. The present review evaluated current evidence on the molecular basis and therapeutic landscape of RCC, with emphasis on von Hippel-Lindau-hypoxia-inducible factor signaling, chromatin remodeling alterations and immune regulatory pathways. The present review summarizes pivotal phase III clinical trials evaluating VEGF-targeted tyrosine kinase inhibitors, mechanistic target of rapamycin inhibitors, immune checkpoint inhibitors and combination regimens, including nivolumab plus ipilimumab, pembrolizumab + axitinib and lenvatinib + pembrolizumab. Emerging biomarkers, including International Metastatic Renal Cell Carcinoma Database Consortium risk stratification, programmed death-ligand 1 expression and chromatin remodeling gene alterations (polybromo 1/BRG1-associated factor 180, BRCA1-associated protein 1 and SET domain containing 2), are discussed in the context of their clinical utility and limitations. Despite marked progress, durable predictive biomarkers and optimal treatment sequencing strategies remain unresolved. Resistance to therapy emerges through adaptive angiogenic signaling, immune escape and metabolic reprogramming, underscoring the need for integrated multi-omics approaches and rational combination strategies. By integrating molecular biology with clinical trial evidence, the present review provides a structured framework for understanding therapeutic decision-making in RCC and highlights future directions toward biomarker-guided precision oncology.
SN - 1791-2997
SN - 1791-3004
ER -